MENU

Pharmaceutical R&D with Metabolomics: Reducing Attrition with Better Models, Compounds and Biomarkers

Pharmaceutical R&D with Metabolomics: Reducing Attrition with Better Models, Compounds and Biomarkers

SPEAKER: Nelson Rhodes, Ph.D., Director of Projects, Pharma and Biotech, Metabolon, Inc.

When scientists and pharmaceutical leaders are asked about the source of high drug attrition rates, they cite many factors including limitations in preclinical models of disease, selection of the right lead compound, and having robust biomarkers to track or segregate patients. In all probability, most of these have a strong degree of contribution, and technologies for addressing all or discrete aspects and are continually evolving.

Metabolomics is a valuable technology that has been proven to address all of the above challenges. Employing a high-throughput, comprehensive metabolic approach in drug discovery and development can provide relevant, interpretable and translatable answers to key biological questions in R&D.

This webinar will convey the utility of metabolomics for:

  • Developing or determining the most appropriate animal model for target/compound evaluation
  • Providing a high-resolution assessment of compounds to add assurance and guidance in candidate selection
  • Elucidating sensitive and specific biomarkers of disease and response